Pulmonary Fibrosis vs. Pulmonary Sclerosis: Differences in Cause, Progression, and Prognosis

Both cause lung scarring and dyspnea, but differ fundamentally:

FeaturePulmonary FibrosisPulmonary Sclerosis
EtiologyDiverse: toxins (asbestos, silica), drugs, autoimmune, genetic, idiopathic (IPF)Usually secondary to chronic inflammation (emphysema, chronic bronchitis)
ProgressionOften rapid, relentlessSlower, more indolent
SeverityMore severe symptoms, faster declineMilder, slower functional loss
PrognosisPoorer; median survival 3–5 years (IPF)Better long-term outlook
TreatmentAntifibrotics (nintedanib, pirfenidone), O₂, rehab, transplantTreat underlying cause, O₂, rehab; transplant rarely needed

Accurate diagnosis (HRCT, biopsy, PFTs) guides therapy. Both benefit from pulmonary rehabilitation and oxygen if hypoxemic.

Multiple Sclerosis - Related Articles